Bayer says eye drug meets goal in diabetic macular edema trials
FRANKFURT Aug 6 (Reuters) - Bayer said on Tuesday that two late-stage studies testing its drug VEGF Trap-Eye against diabetic macular edema (DME) met their primary goals.
Bayer co-develops the eye drug, also known as Eylea, with Regeneron.
Bayer said that Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, about a year earlier that previously planned.
- Tweet this
- Share this
- Digg this
- British Muslims blame jihadi subculture after beheading video
- Merkel says tightening Ukraine-Russian border is key to peace deal |
- Bombs kill at least 35 across Iraq a day after mosque shooting |
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky, Syria activist says